Open Orphan shares at centre of insider trading probe Specialist pharmaceutical services company Open Orphan says it has been made aware of an allegation of potential insider trading of its shares and is helping … Business • 15 Sep 22
Open Orphan opens two new testing facilities Specialist pharmaceutical services clinical research company Open Orphan is opening a new primary FluCamp volunteer recruitment screening facility in London and a secondary FluCamp recruitment … Business • 08 Mar 22
Open Orphan names Khan as new CEO Specialist pharmaceutical services clinical research company Open Orphan has appointed Yamin 'Mo' Khan as its chief executive with immediate effect. Business • 24 Feb 22
Open Orphan's hVIVO wins RSV human challenge study deal Specialist pharmaceutical services clinical research company Open Orphan said its hVIVO subsidiary has signed a £5.1m contract with a biopharmaceutical company to use its respiratory … Business • 17 Nov 21
Open Orphan's Venn secures contract renewal deal Specialist pharmaceutical company Open Orphan said its subsidiary Venn Life Sciences has agreed a contract renewal deal with a major global pharmaceutical client worth £1.5m … Business • 15 Nov 21
Open Orphan's Poolbeg Pharma to list on London's AIM Pharmaceutical firm Open Orphan has today announced plans to spin out a Dublin-headquartered company focused on infectious diseases, called Poolbeg Pharma. Business • 17 Jun 21
Open Orphan considers spinning out assets Specialist pharmaceutical services clinical research company, Open Orphan, is considering a possible spin-out of certain non-core development intellectual property assets. Business • 13 Apr 21
Volunteers complete 'quarantine phase' of Covid study Dublin-listed pharmaceutical company Open Orphan has said the first three volunteers have now successfully completed the quarantine phase of their 'Covid-19 characterisation study' with no … Business • 25 Mar 21
Open Orphan agrees Covid contract with UK government Dublin-listed pharmaceutical company Open Orphan said its subsidary hVIVO has agreed a deal with the UK government to develop a Covid-19 human challenge study model. Business • 20 Oct 20
Open Orphan wins new £4.3m challenge study deal Dublin-listed pharmaceutical company Open Orphan has announced a new £4.3m contract to conduct a human viral challenge study using one of its eight traditional challenge … Business • 28 Sep 20
Open Orphan signs €4.4m contract with global company Pharmaceutical services company, Open Orphan has signed a new contract, valued at €4.4m, with a global pharmaceutical company to provide a respiratory syncytial virus (RSV) … Business • 10 Aug 20
Open Orphan agrees contract for Covid-19 vaccine trial Dublin-listed pharmaceutical company Open Orphan has announced a new contract with Codagenix to conduct a first human trial evaluating safety and immunogenicity of a single-dose … Business • 28 Jul 20
Open Orphan agrees option to buy CHIMagents Dublin-listed pharmaceutical services group Open Orphan has signed an option to buy a company called CHIMagents. The company designs and makes "challenge agents", which are … Business • 15 Jul 20
Open Orphan develops challenge study model for vaccines Dublin listed pharmaceutical company Open Orphan has said it is developing the world's first challenge study model to test the effectiveness of a number of … Business • 24 Jun 20
Open Orphan raises £12m for Covid-19 testing Irish pharmaceutical firm Open Orphan has raised £12m, which it will put towards the hunt to find a vaccine for Covid-19. Business • 22 May 20
Open Orphan CEO to leave the company Chief executive of specialist pharmaceutical company, Open Orphan, Trevor Phillips is to leave the firm, it has been announced. Business • 04 May 20
Open Orphan to buy hVIVO in £30m merger deal Irish pharmaceutical firm Open Orphan has agreed to a merger deal with British firm hVIVO, which would create a group valued at around £30m. Business • 09 Dec 19
